114 related articles for article (PubMed ID: 15225143)
1. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
Chan DC; Barrett PH; Watts GF
Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
[TBL] [Abstract][Full Text] [Related]
3. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
Watts GF; Chan DC; Ooi EM; Nestel PJ; Beilin LJ; Barrett PH
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):877-82. PubMed ID: 16922825
[TBL] [Abstract][Full Text] [Related]
4. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
Chan DC; Barrett PH; Watts GF
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states.
Chan DC; Watts GF
Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
Chan DC; Barrett PH; Watts GF
Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
Watts GF; Ooi EM; Chan DC
Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
[TBL] [Abstract][Full Text] [Related]
8. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders.
Chan DC; Barrett PH; Watts GF
Curr Opin Lipidol; 2006 Feb; 17(1):28-36. PubMed ID: 16407713
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Chan DC; Barrett HP; Watts GF
Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
[TBL] [Abstract][Full Text] [Related]
10. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
[TBL] [Abstract][Full Text] [Related]
11. Unravelling lipoprotein metabolism with stable isotopes: tracing the flow.
Ying Q; Chan DC; Barrett PHR; Watts GF
Metabolism; 2021 Nov; 124():154887. PubMed ID: 34508741
[TBL] [Abstract][Full Text] [Related]
12. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men.
Chan DC; Barrett PH; Ooi EM; Ji J; Chan DT; Watts GF
J Clin Endocrinol Metab; 2009 Mar; 94(3):989-97. PubMed ID: 19116237
[TBL] [Abstract][Full Text] [Related]
13. Association between skeletal muscle fat content and very-low-density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss.
Chan DC; Gan SK; Wong AT; Barrett PH; Watts GF
Diabetes Obes Metab; 2014 Oct; 16(10):994-1000. PubMed ID: 24821431
[TBL] [Abstract][Full Text] [Related]
14. Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism.
Chan DC; Barrett PH; Watts GF
Curr Opin Lipidol; 2016 Dec; 27(6):550-556. PubMed ID: 27749370
[TBL] [Abstract][Full Text] [Related]
15. [Disturbances of lipoprotein metabolism in metabolic syndrome].
Czyzewska M; Wolska A; Cwiklińska A; Kortas-Stempak B; Wróblewska M
Postepy Hig Med Dosw (Online); 2010 Jan; 64():1-10. PubMed ID: 20093718
[TBL] [Abstract][Full Text] [Related]
16. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
17. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the investigation of lipoprotein metabolism using tracer methodology.
Chan DC; Watts GF
Clin Lab; 2006; 52(7-8):353-61. PubMed ID: 16955633
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A-II and adiponectin as determinants of very low-density lipoprotein apolipoprotein B-100 metabolism in nonobese men.
Chan DC; Watts GF; Ooi EM; Chan DT; Wong AT; Barrett PH
Metabolism; 2011 Oct; 60(10):1482-7. PubMed ID: 21550083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
